PPHM Peregrine Pharmaceuticals, Inc. Today's

New Post Public Reply Private Reply Replies (0) Message Board
Tao
PPHM Peregrine Pharmaceuticals, Inc.

Today's Technical View on Sequenom, Peregrine Pharma, Inovio Pharma, and Onyx Pharma
LONDON, April 12, 2013 /PRNewswire via COMTEX/ -- Markets showed broad gains as these continued their upward ascent. The new earnings season has started on a positive note and provided a good fillip to the stocks. Unemployment benefit data also showed decline, raising optimism about the pace of economic growth. Major indices like The Dow Jones Index and S&P500 are trading at all time high. Healthcare sector remained robust and our research team tracked major companies like Sequenom Inc. (NASDAQ: SQNM) and Peregrine Pharmaceuticals (NASDAQ: PPHM), which remained subdued. On the other hand, Inovio Pharmaceuticals Inc. (NYSE: INO) and Onyx Pharmaceuticals Inc. (NASDAQ: ONXX) showed good gains. StockCall initiated free in-depth technical analysis on SQNM, PPHM, INO, and ONXX which are currently available upon sign up at

http://www.stockcall.com/research

Sequenom Inc. is trading above its long-term moving average price, indicating a bullish trend. It also closed its latest trading session at $4.08, same as its previous close. The stock traded below average volume of 2.34 million shares. Sequenom trades at beta of 0.07, implying very low volatility. However, the stock declined 9.33 percent this year while it gained 5.15 percent in the past 52 weeks. Sequenom commands market capitalization of $469.81 million. The stock is likely to go up to $4.18 price level in the coming trading sessions. Sign up for the free technical analysis on SQNM at

http://www.StockCall.com/SQNM041213.pdf

Peregrine Pharmaceuticals closed Thursday's session at $1.37, down 0.72 percent. The stock is currently in the neutral mode and may touch $1.29 level in the coming days. Upon breaching this level, the stock's next support price is at $1.21. Peregrine's stock is mildly volatile with its beta at 0.91. So far in 2013, the stock appreciated 11.38 percent. Its 52 weeks gain stands at 180.34 percent. The stock has traded in the range of $0.39 and $5.50 during the said time period. The company commands market capitalization of $187.84 million. Download the free report on PPHM by registering at

http://www.StockCall.com/PPHM041213.pdf

Inovio Pharmaceuticals Inc. trimmed its 52-weeks loss by closing 2.81 percent higher. The stock ended yesterday's session at $0.586, while its highest price point for the session stood at $0.59. It traded 2.12 million shares, down from its average daily volume of 2.23 million. Inovio traded in the range of $0.38 and $0.83 in the past 52 weeks and commands market capitalization of $106.16 million. The company reported its latest EPS at -$0.15. Stocks of INO lost more than 12 percent in the past 52 weeks. It is highly volatile with beta of 2.81. The free report on INO can be downloaded by signing up now at

http://www.StockCall.com/INO041213.pdf

Onyx Pharmaceuticals Inc. closed its latest trading session at $97.07, up 2.87 percent from its previous close. The stock traded in the range of $94.51 and $99.40 in the session and traded 1.93 million shares. It is likely to face its first resistance level at $97.55 and upon breaching this level the stock may go up to $97.96. On the downside, Onyx Pharmaceuticals may tumble to $93.05 level. The stock is volatile as it sports the beta of 1.15. So far in 2013, it gained 28.33 percent whereas in the past 52 weeks, it gained 133.96 percent of its value. The stock is in a bullish mode. Free report on ONXX can be accessed by registering at

http://www.StockCall.com/ONXX041213.pdf

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at

http://www.stockcall.com

SOURCE StockCall.com

http://rt.prnewswire.com/rt.gif?NewsItemId=en...d=20130412

  www.prnewswire.com  
 
 Copyright (C) 2013 PR Newswire. All rights reserved
 
**********************************************************************

As of Monday, 04-08-2013 23:59, the latest Comtex SmarTrend? Alert, an automated pattern recognition system, indicated a DOWNTREND on 04-27-2012 for INO @ $0.54.

For more information on SmarTrend, contact your market data provider or go to www.mysmartrend.com

SmarTrend is a registered trademark of Comtex News Network, Inc. Copyright ? 2004-2013 Comtex News Network, Inc. All rights reserved.

-0-

 KEYWORD:          United States of America
                  United Kingdom
INDUSTRY KEYWORD: FIN
                  WEB
SUBJECT CODE:     INO
 

Data Presented at AACR Annual Meeting Support Targeted Immune Reactivation Mechanism and Potential of Peregrine's Bavituximab in Solid Tumor Therapy
Imaging Studies Show Docetaxel Strongly Upregulates Bavituximab's PS Target in Tumors, Further Supporting Lead Clinical Indication in Second Line Non-Small Cell Lung Cancer; Preclinical Studies Support Potential of Bavituximab to Induce Cancer-Fighting Changes in Immune Response to Tumors That Have Been Associated With Prolonged Survival in Lung Cancer Patients
TUSTIN, CA, Apr 10, 2013 (Marketwired via COMTEX) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today highlighted data presented at the Annual Meeting of the American Association for Cancer Research (AACR). Data was presented this week from preclinical studies investigating the immune-stimulating mechanism of action of Peregrine's lead phosphatidylserine (PS)-targeting oncology clinical candidate bavituximab and the anti-tumor and imaging potential of other PS-targeting molecules. Bavituximab is currently being evaluated in several oncology clinical trials including the lead indication of second-line non-small cell lung cancer (NSCLC), which is anticipated to advance into a pivotal Phase III trial later this year.

"These studies yield important insights into the fundamental role that exposed PS plays in tumor immune evasion, and further support our lead clinical candidate bavituximab's ability to reactivate tumor immunity. This is now clearly evidenced by several specific measurements of both the immune-stimulating and anti-tumor mechanisms mediated by PS-targeting antibodies as well as imaging studies demonstrating that tumor growth inhibition is correlated with PS expression levels in tumors," said Jeff T. Hutchins, Ph.D., vice president of preclinical research at Peregrine Pharmaceuticals. "Included in these presentations was a compelling finding of a pronounced antibody-mediated increase in tumor-fighting immune cells that is independently correlated with an impressive survival benefit in patients with NSCLC based on a published retrospective study of clinical data(1). When taken together, these results support PS as a promising oncology drug target and provide additional rationale for the impressive Phase II survival data we have seen in bavituximab's lead indication of second-line NSCLC."

Data presented from imaging studies(2) demonstrate that the chemotherapeutic drug docetaxel, a commonly prescribed second-line treatment for patients with advanced NSCLC, increases the exposure of bavituximab's target molecule, phosphatidylserine (PS), on tumor blood vessel cells and tumor cells. Results also showed that PS exposure in tumors is correlated with tumor burden and response to docetaxel treatment, supporting exposed PS as a promising biomarker of cancer and response to therapy. Peregrine's PS-targeting imaging agent I-124-PGN650 is currently being evaluated in a clinical trial to assess its safety and potential to image multiple tumor types in patients with cancer.

Additional data presented from a series of preclinical studies(3) demonstrate that PS-targeting antibodies mediate immuno-stimulatory changes in tumors resulting in an increase of tumor-fighting (M1) macrophages, immune cells strongly associated with survival benefits in patients with NSCLC(1). Peregrine recently reported promising data from a randomized, double-blind, placebo-controlled Phase II second-line NSCLC clinical trial demonstrating a 60% improvement in median overall survival (OS) in patients receiving 3 mg/kg bavituximab plus docetaxel compared to the control arm. The company plans to meet with the U.S. Food and Drug Administration (FDA) in the second quarter of calendar year 2013 with the goal of initiating a Phase III trial by calendar year-end.

Researchers also presented details of new PS-binding constructs(4). Termed "betabodies," the molecules consist of the PS-binding domain of the serum protein ?2-glycoprotein I (?2GPI), fused to the constant region of an antibody. Betabodies bind to PS directly, are smaller in size and have a longer serum half-life than natural antibodies. Early studies indicate that betabodies hold potential as next-generation PS-binding agents that have the potential to be used for a broad number of applications including antibody-drug conjugates and next generation therapeutics for oncology and infectious diseases.

(1) The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time. Ma et al. BMC Cancer 2010, 10:112. Open access research article: http://www.biomedcentral.com/content/pdf/1471...10-112.pdf

Presentation Details

(2) Jian Gong(1), Richard Archer(1), Van Nguyen(1), Christopher C.W. Hughes(2), Jeff Hutchins(1), Bruce Freimark(1). 1. Peregrine Pharmaceuticals, Inc., Tustin, CA; 2. University of California, Irvine, Irvine, CA. Predicting anti-tumor responses to phosphatidylserine targeting antibodies using tumor imaging. In Proceedings of the 104th Annual Meeting of the American Association for Cancer Research (AACR); 2013 Apr 6-10; Washington, D.C. Abstract 2850

(3) Yi Yin, Xianming Huang, Dan Ye, Philip Thorpe. UT Southwestern Medical Ctr., Dallas, TX: Phosphatidylserine-targeting antibody reactivates tumor immunity and destroys tumor vasculature in mice. In Proceedings of the 104th Annual Meeting of the American Association for Cancer Research (AACR); 2013 Apr 6-10; Washington, D.C. Abstract 1244

(4) Xianming Huang(1), Dan Ye(1), Troy Luster(2), E. Sally Ward(1), Philip Thorpe(1). 1. UT Southwestern Medical Ctr., Dallas, TX; 2. Human Genome Science, Maryland, MD. Phosphatidylserine-targeting 'betabodies' for the treatment of cancer. In Proceedings of the 104th Annual Meeting of the American Association for Cancer Research (AACR); 2013 Apr 6-10; Washington, D.C. Abstract 4326

Copies of the AACR posters are available at Peregrine's website at http://www.peregrineinc.com/technology/bavitu...-data.html

About Bavituximab Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that represents a new approach to treating cancer. Bavituximab is the lead drug candidate from the company's PS technology platform and is currently being tested in eight clinical trials, including three randomized Phase II trials in front-line and second-line non-small cell lung cancer and front-line pancreatic cancer, and five investigator-sponsored trials (ISTs) in additional oncology indications. PS is a highly immunosuppressive molecule usually located inside the membrane of healthy cells, but "flips" and becomes exposed on the outside of cells that line tumor blood vessels, creating a specific target for anti-cancer treatments. PS-targeting antibodies target and bind to PS and block this immunosuppressive signal, thereby enabling the immune system to recognize and fight the tumor.

About Peregrine Pharmaceuticals, Inc. Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials focused on the treatment and diagnosis of cancer. The company is pursuing multiple clinical programs in cancer with its lead product candidate bavituximab and novel brain cancer agent Cotara(R). Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. ( www.avidbio.com ), which provides development and biomanufacturing services for both Peregrine and third-party customers. Additional information about Peregrine can be found at www.peregrineinc.com .

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the major discrepancies discovered with respect to our randomized, double-blind placebo-controlled Phase II trial of bavituximab in patients with refractory NSCLC may cause regulatory authorities to require further clinical trials to support a registration package, the risks that partnering discussions may not result in a partnering transaction or that such discussions could be hindered or delayed as a result of the potential impact on the regulatory pathway for bavituximab caused by the major discrepancies discovered with respect to the Phase II NSCLC trial or the existing class action lawsuits, the risk that the Company may not be able to initiate a the pivotal Phase III trial within its anticipated timeline, the risk that Peregrine may not have or raise adequate financial resources to complete its other planned clinical programs and the risk that the data from future clinical studies may not be consistent with the data from the above preclinical studies. It is important to note that the Company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in our reports filed with the Securities and Exchange Commission including, but not limited to, our annual report on Form 10-K for the fiscal year ended April 30, 2012 and our quarterly report on Form 10-Q for the quarter ended January 31, 2013. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

 Contact:
Christopher Keenan or Jay Carlson
Peregrine Pharmaceuticals, Inc.
(800) 987-8256
info@peregrineinc.com 


 
SOURCE: Peregrine Pharmaceuticals
 CONTACT:          mailto:info@peregrineinc.com

 
 (C) 2013  Marketwire L.P.  All rights reserved.
 
-0-
 SUBJECT CODE:     Pharmaceuticals and Biotech:Biotech
                  Pharmaceuticals and Biotech:Trials
                  Pharmaceuticals and Biotech rugs
 
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 78

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 69

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Kinross Lawsuit Puts Round Mountain Claims Under Fire

Updated Category News Views 85

A mine can swallow a rosy forecast faster than any spreadsheet admits. That is the ugly center of the proposed securities class action involving Kinross Gold: not merely that production guidance came down, but the allegation that investors were sold too much confidence before the operational reality at Round Mountain Phase S surfaced. NYSE:KGC dropped from $27.62 on...

Continue Reading
ASA’s 2026 Grants Push Dermatology Into New Terrain

Updated Category News Views 104

Thirteen Small Bets With Serious Human Stakes Skin science rarely gets the splashy headlines, yet it touches a staggering number of people and carries some very stubborn unanswered questions. American Skin Association’s 2026 grant class puts 13 awards across skin cancer and dermatologic disease, with a noticeable willingness to follow newer clinical terrain rather than...

Continue Reading
KONST Pitches Asia GPU Uptime as AI Demand Gets Real

Updated Category News Views 131

GPU racks are easy to admire when the lights are on; keeping them useful at 3 a.m. is where the bruises show. KONST arrived at SC26 in Chicago with a sensible pitch for an AI-infrastructure market that is getting less impressed by shiny hardware lists and more obsessed with whether the thing actually works. Its theme, “24/7 GPUs Delivered in Asia,” puts the emphasis...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 169

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 53

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
Highmark’s 2026 Rebound Has a Few Asterisks Attached

Updated Category News Views 74

The Headline Needs a Pencil, Not a Highlighter A $1.9 billion net-income figure can look downright thunderous until you separate the cash-generating engine from the accounting cargo strapped to it. Highmark Health reported $26.5 billion in revenue and $741 million in operating income for the nine months ended Sept. 30, 2026. Those are materially better numbers than the...

Continue Reading
Oatly’s $4.13 Tender Offer Is a Legal Detour, Not a Sale

Updated Category News Views 161

A $4.13 cash offer trading against a $7.17 close is the sort of thing that makes investors squint hard, and Verlinvest is practically waving a flag telling them why. This is not a conventional attempt to buy Oatly Group AB. It is a technical tender offer built to satisfy Swedish takeover rules while Verlinvest buys out its joint-venture partner’s interest in Oatly’s...

Continue Reading
Greenberg Traurig Adds Privacy Muscle in Denver Office

Updated Category News Views 162

Privacy work used to be the legal department's back-room plumbing; now it can jam an entire product launch. That is why Greenberg Traurig's decision to bring Amber Mednick in as of counsel in Denver deserves more attention than the usual law-firm hiring blurb. This is not a splashy deal, and nobody should pretend one lateral hire rewrites the competitive map. Still, it is...

Continue Reading

Top 5 Most Recently Viewed Articles

Leech Tishman Expands Healthcare Practice with Nelson Hardiman

Updated Category News Views 79

Leech Tishman Expands Its Healthcare Practice with Major Addition Leech Tishman is making a significant move in its growth strategy by merging with the respected healthcare firm, Nelson Hardiman. This collaboration is set to enhance Leech Tishman’s footprint in the healthcare sector, especially in the Southern California region, as they prepare to operate under the name...

Continue Reading
Schouw & Co. Announces Success in Share Buy-Back Program

Updated Category News Views 105

Schouw & Co. Share Buy-Back Program Overview Schouw & Co., a notable player in the business landscape, has embarked on an impactful share buy-back program that began recently. This strategic move allows the company to purchase shares worth up to DKK 50 million over a designated time frame, from January 2 to March 31. Such initiatives reflect the company's commitment to...

Continue Reading
Earnings Season Set to Shape Market Dynamics Amid Tariffs

Updated Category News Views 150

Understanding Market Sentiment During Earnings Season The upcoming earnings season presents an opportunity for Wall Street to shift its attention from external geopolitical factors to the internal dynamics of corporate performance. As companies prepare to unveil their second-quarter earnings reports, a closer look at how tariffs could influence consumer spending and,...

Continue Reading
Josh Ruben Joins the Board of PetVivo Holdings to Drive Growth

Updated Category News Views 316

Josh Ruben Joins PetVivo Holdings, Inc. Board of Directors PetVivo Holdings, Inc. (OTCQX: PETV; OTCID: PETVW) has announced the addition of Josh Ruben to its Board of Directors. This news comes from the company's efforts to further establish itself within the biomedical device sector aimed at improving the quality of life for companion animals. Transformational Leadership...

Continue Reading
Innovative Portable Solar and Wind Generator Concept Unveiled

Updated Category News Views 120

Your Sustainable Charging Solution We live in a time where sustainable energy solutions are becoming more paramount, and the invention of a portable solar and wind-powered generator meets that demand head-on. The concept builds on the idea that everyone deserves access to clean energy alternatives, especially for charging electronic devices. The Vision Behind the...

Continue Reading